1	SENATE FLOOR VERSION February 21, 2022		
2			
3	COMMITTEE SUBSTITUTE FOR		
4	SENATE BILL NO. 1413 By: Montgomery of the Senate		
5	and		
6	Sneed of the House		
7			
8			
9	An Act relating to mental health parity; amending 36 O.S. 2021, Section 6060.11, which relates to mental		
10	health coverage provisions; modifying contents to be reported in analyses; updating statutory references to comply with federal law; requiring analysis findings include certain provisions; requiring Insurance Commissioner promulgate rules and standardized reporting materials; updating statutory references; updating statutory language; and		
11			
12			
13			
14	providing an effective date.		
15			
16	BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:		
17	SECTION 1. AMENDATORY 36 O.S. 2021, Section 6060.11, is		
18	amended to read as follows:		
19	Section 6060.11. A. Subject to the limitations set forth in		
20	this section and Sections 6060.12 and 6060.13 of this title, any		
21	health benefit plan that is offered, issued, or renewed in this		
22	state on or after the effective date of this act January 1, 2000,		
23	shall provide benefits for treatment of mental health and substance		
24	use disorders.		

B. 1. Benefits for mental health and substance use disorders
shall be equal to benefits for treatment of and shall be subject to
the same preauthorization and utilization review mechanisms and
other terms and conditions as all other physical diseases and
disorders including, but not limited to:

- a. coverage of inpatient hospital services for either
 twenty-six (26) days or the limit for other covered
 illnesses, whichever is greater,
- 9 b. coverage of outpatient services,
- 10 c. coverage of medication,
- 11 d. maximum lifetime benefits,
- 12 e. copayments,
- 13 f. coverage of home health visits,
- 14 g. individual and family deductibles, and
- 15 h. coinsurance.

16 2. Treatment limitations applicable to mental health or 17 substance use disorder benefits shall be no more restrictive than 18 the predominant treatment limitations applied to substantially all 19 medical and surgical benefits covered by the plan. There shall be 20 no separate treatment limitations that are applicable only with 21 respect to mental health or substance abuse disorder benefits.

C. A health benefit plan shall not impose a nonquantitative treatment limitation with respect to mental health and substance use disorders in any classification of benefits unless, under the terms

of the health benefit plan as written and in operation, any processes, strategies, evidentiary standards or other factors used in applying the nonquantitative treatment limitation to mental health disorders in the classification are comparable to and applied no more stringently than to medical and surgical benefits in the same classification.

D. All health benefit plans must meet the requirements of the
federal Paul Wellstone and Pete Domenici Mental Health Parity and
Addiction Equity Act of 2008, as amended, and federal guidance or
regulations issued under these acts including 45 CFR 146.136, 45 CFR
147.160, and 45 CFR 156.115(a)(3), 42 U.S.C. 300gg-26(a), 29 U.S.C.
1185a(a), and 26 U.S.C. 9812.

E. Beginning on or after the effective date of this act January 14 <u>1, 2000</u>, each insurer that offers, issues or renews any individual or group health benefit plan providing mental health or substance use disorder benefits shall submit an annual report to the Insurance Commissioner on or before April 1 of each year that contains the following:

A description of the process used to develop or select the
 medical necessity criteria for mental health and substance use
 disorder benefits and the process used to develop or select the
 medical necessity criteria for medical and surgical benefits;
 Identification of all nonquantitative treatment limitations
 applied to both mental health and substance use disorder benefits

1 and medical and surgical benefits within each classification of 2 benefits; and

The results of an analysis that demonstrates that for the 3 3. medical necessity criteria described in paragraph 1 of this 4 5 subsection and for each nonquantitative treatment limitation identified in paragraph 2 of this subsection, as written and in 6 operation, the processes, strategies, evidentiary standards or other 7 factors used in applying the medical necessity criteria and each 8 9 nonquantitative treatment limitation to mental health and substance use disorder benefits within each classification of benefits are 10 11 comparable to and are applied no more stringently than to medical 12 and surgical benefits in the same classification of benefits. At a 13 minimum, the results of the analysis shall:

- a. identify <u>and clearly define</u> the factors <u>and terms</u> used
 to determine that a nonquantitative treatment
 limitation will apply to a benefit including factors
 that were considered but rejected,
- b. identify and <u>clearly</u> define the specific evidentiary
 standards used to define the factors and any other
 evidence relied upon in designing each nonquantitative
 treatment limitation,
- c. provide the <u>detailed</u>, written, and reasoned
 comparative analyses including the results of the
 analyses performed to determine that the processes and

strategies used to design each nonquantitative treatment limitation, as written, and the as written processes and strategies used to apply the nonquantitative treatment limitation to mental health and substance use disorder benefits are comparable to and applied no more stringently than the processes and strategies used to design each nonquantitative treatment limitation, as written, and the as written processes and strategies used to apply the nonquantitative treatment limitation to medical and surgical benefits,

12 d. provide the detailed, written, and reasoned comparative analyses including the results of the 13 analyses performed to determine that the processes and 14 strategies used to apply each nonquantitative 15 treatment limitation, in operation, for mental health 16 and substance use disorder benefits are comparable to 17 and applied no more stringently than the processes or 18 strategies used to apply each nonquantitative 19 treatment limitation for medical and surgical benefits 20 in the same classification of benefits, and 21 disclose the specific findings and conclusions reached 22 e. by the insurer that the results of the analyses 23 required by this subsection indicate that whether the 24

SENATE FLOOR VERSION - SB1413 SFLR (Bold face denotes Committee Amendments)

1

2

3

4

5

6

7

8

9

10

11

1	insurer is in compliance with this section and the			
2	Paul Wellstone and Pete Domenici Mental Health Parity			
3	and Addiction Equity Act of 2008, as amended, and its			
4	implementing and related regulations including 45 CFR			
5	146.136, 45 CFR 147.160 <u>,</u> and 45 CFR 156.115(a)(3) <u>, 42</u>			
6	U.S.C. 300gg-26(a), 29 U.S.C. 1185a(a), and 26 U.S.C.			
7	<u>9812</u> .			
8	F. The findings and conclusions shall include sufficient detail			
9	to fully explain such findings including methodologies for the			
10	analyses, detailed descriptions of each treatment limitation for			
11	mental health and substance use disorder benefits compared to each			
12	treatment limitation for medical and surgical benefits, and detailed			
13	descriptions of all criteria involved for approving mental health			
14	and substance use disorder benefits as compared to the criteria			
15	involved for approving medical and surgical benefits.			
16	<u>G.</u> The Commissioner shall implement and enforce any applicable			
17	provisions of the Paul Wellstone and Pete Domenici Mental Health			
18	Parity and Addiction Equity Act of 2008, as amended, and federal			
19	guidance or regulations issued under these acts including 45 CFR			
20	146.136, 45 CFR 147.136, 45 CFR 147.160 <u>, and</u> 45 CFR 156.115(a)(3) <u>,</u>			
21	42 U.S.C. 300gg-26(a), 29 U.S.C. 1185a(a), and 26 U.S.C. 9812.			
22	H. The Commissioner shall promulgate rules and standardized			
23	reporting templates to ensure compliance with the provisions of this			
24	section. Guidance shall include examples of non-quantitative			

<u>treatment limitations as identified by the Centers for Medicare and</u>
 <u>Medicaid Services, the Department of Labor, and the Employee</u>
 Benefits Security Administration.

G. I. No later than December 31, 2021, and by December 31 of
each year thereafter, the Commissioner shall make available to the
public the reports submitted by insurers, as required in subsection
E of this section, during the most recent annual cycle; provided,
however, that any information that is confidential or a trade secret
shall be redacted.

The Commissioner shall identify insurers that have failed in
 whole or in part to comply with the full extent of reporting
 required in this section and shall make a reasonable attempt to
 obtain missing reports or information by June 1 of the following
 year.

The reports submitted by insurers and the identification by
 the Commissioner of noncompliant insurers shall be made available to
 the public by posting on the Internet website of the Insurance
 Department. Any information that is confidential or a trade secret
 shall be redacted prior to the public posting.

20 H. J. The Commissioner shall may promulgate rules pursuant to 21 the provisions of this section and any provisions of the Paul 22 Wellstone and Pete Domenici Mental Health Parity and Addiction 23 Equity Act of 2008, as amended, that relate to the business of 24 insurance.

1	1 SECTION 2. This act shall become e	ffective November 1, 2022.
2	2 COMMITTEE REPORT BY: COMMITTEE ON RETIR February 21, 2022 - DO PASS AS AMENDED	EMENT AND INSURANCE
3		
4	4	
5	5	
6	6	
7	7	
8	8	
9	9	
10	0	
11	1	
12	2	
13	3	
14	4	
15	5	
16	6	
17	7	
18	8	
19	9	
20	0	
21	1	
22	2	
23	3	
24	4	